Dr. O'Sullivan on Safety Profile of Radium-223

Joe OSullivan, MD
Published: Wednesday, Dec 16, 2015



Joe O'Sullivan, MD, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Centre for Cancer Research and Cell Biology, at Queen’s University Belfast, discusses toxicities associated with radium-223 dichloride for patients with metastatic castration-resistant prostate cancer.

Toxicities that were observed in patients enrolled in the ALSYMPCA trial as well as the expanded access program associated with radium-223 were similar, O’Sullivan says. This included a 5% to 6% rate of grade 3 thrombocytopenia, though this is generally reversible. Also reported were low rates anemia or neutropenia.

Non-hematologic toxicities include diarrhea, O’Sullivan adds.
 
SELECTED
LANGUAGE


Joe O'Sullivan, MD, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Centre for Cancer Research and Cell Biology, at Queen’s University Belfast, discusses toxicities associated with radium-223 dichloride for patients with metastatic castration-resistant prostate cancer.

Toxicities that were observed in patients enrolled in the ALSYMPCA trial as well as the expanded access program associated with radium-223 were similar, O’Sullivan says. This included a 5% to 6% rate of grade 3 thrombocytopenia, though this is generally reversible. Also reported were low rates anemia or neutropenia.

Non-hematologic toxicities include diarrhea, O’Sullivan adds.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x